Employees: 1-10
Total raised: $16.7M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 03.05.2022 | Seed | $16.7M | - |
Mentions in press and media 6
| Date | Title | Description | Source |
| 22.12.2023 | Clinical progress for three Biotechs | DIAMOND-1 (DIAbetic Macular edema patients ON a Drop) Phase 3 trial by Oculis’ OCS-01 eye drops ai... | startuptic... |
| 13.07.2023 | Startups gather Board members’ expertise | Versameb is transforming (m)RNA therapeutics to cure hard-to-treat and/or prevalent diseases with ... | startuptic... |
| 10.05.2023 | Leadership changes in startups' C-Suites | Engimmune Therapeutics AG, a Swiss biotech company developing novel T-cell receptor (TCR)-based th... | startuptic... |
| 05.05.2022 | Switzerland's Engimmune Therapeutics scores €15M seed | Engimmune Therapeutics has received 15.5 million Swiss francs (about €15 million) in a round led by ... | pitchbook.... |
| 03.05.2022 | Engimmune Therapeutics raises CHF 15.5 million in seed finan... | TCR-based therapies are an emerging class of drugs, however, when developing therapies, the challe... | startuptic... |
| 03.05.2022 | Engimmune Therapeutics Raises CHF 15.5M in Seed Financing | Engimmune Therapeutics, a Basel, Switzerland-based biotech company developing novel T-cell receptor ... | finsmes.co... |